international
To sponsor this category, click here | subscribe to this category

Dassault Systemes profit jumps; outlook raised

LOS ANGELES (MarketWatch) — Dassault Systemes said Thursday its second-quarter profit totaled 48.6 million euros ($63.2 million), or €0.40 a share, from €25.6 million, or €0.22 a share, in the same quarter a year before, according to International Financial Reporting Standards. Revenue for the quarter was €385.6 million, rising from €310.9 million in the year-ago period. The company also raised its revenue growth outlook to “about 22% to 25% in constant currencies” for the second half of the year.

Interest grows in training grants for life sciences companies

PRA International is poised to become the first life sciences company in the region to take advantage of a new grant program designed to offset a portion of the expenses an employer incurs training new workers.

Baxter International Q2 2010 Earnings Call Transcript

Baxter International ( BAX ) Q2 2010 Earnings Call July 22, 2010 8:30 am ET Complete Story

Shionogi, GSK move HIV drug into PhIII

GlaxoSmithKline ( NYSE: GSK ) and partner Shionogi say they are bringing their once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 into Phase III trials.

New Guidelines Urge Earlier Therapy for HIV Patients (HealthDay)

HealthDay – SUNDAY, July 18 (HealthDay News) — Starting antiretroviral treatment (ART) when an HIV patient has no symptoms can prevent the progressive immune system destruction that leads to AIDS, according to new treatment guidelines released by the International AIDS Society-USA Panel.

Vaginal Gel Cuts Risk of HIV Infection, Study Shows (HealthDay)

HealthDay – MONDAY, July 19 (HealthDay News) — A vaginal gel applied consistently before and after sex reduced the risk of HIV infection by more than half, according to a study presented Monday at the International AIDS Conference in Vienna.

Global economic crisis threatens fight against AIDS (AFP)

AFP – The global fight against HIV/AIDS is threatened by stagnating economies around the world, which have caused governments to shrink their budgets and, with them, grants to fight the illness.

An Avandia Study Author…Or So We Thought?

Steve Haffner played a relatively modest role in the Avandia scandal, but until now, he was known primarily for leaking to GlaxoSmithkline the damaging meta-analysis of the diabetes pill that was published in The New England Journal of Medicine three years ago. Haffner later acknowledged breaching his responsibility as a peer reviewer, but blamed “bad judgment” because he wasn’t “feeling well.” In doing so, Glaxo was able to respond very quickly to the disclosure ( back story ). As it happens, Haffner felt just fine several years earlier when he allegedly had an Avandia study ghostwritten for him

The XVIII International AIDS Conference – Everything Has Changed

How many “talented people” have lost jobs in the pharma industry this year? A response to John Lechleiter on America’s Growing Innovation Gap

John Lechleiter, CEO of Lilly, wrote an interesting piece in today’s Wall Street Journal. While he brings up some valid points I believe that the drug industry itself has to take a look in the mirror and acknowledge its responsibility for the mess they are in today. According to Mr Lechleiter: A recent study ranked the U.S.